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Abstract: The International Association for the Study of Lung
Cancer (IASLC) Board of Directors convened a computed tomog-
raphy (CT) Screening Task Force to develop an IASLC position
statement, after the National Cancer Institute press statement from
the National Lung Screening Trial showed that lung cancer deaths
fell by 20%. The Task Force’s Position Statement outlined a number
of the major opportunities to further improve the CT screening in
lung cancer approach, based on experience with cancer screening
from other organ sites.
The IASLC CT Screening Workshop 2011 further developed
these discussions, which are summarized in this report. The recom-
mendation from the workshop, and supported by the IASLC Board
of Directors, was to set up the Strategic CT Screening Advisory
Committee (IASLC-SSAC). The Strategic CT Screening Advisory
Committee is currently engaging professional societies and organi-
zations who are stakeholders in lung cancer CT screening imple-
mentation across the globe, to focus on delivering guidelines and
recommendations in six specific areas: (i) identification of high-risk
individuals for lung cancer CT screening programs; (ii) develop
radiological guidelines for use in developing national screening
programs; (iii) develop guidelines for the clinical work-up of “in-
determinate nodules” resulting from CT screening programmers;
(iv) guidelines for pathology reporting of nodules from lung cancer
CT screening programs; (v) recommendations for surgical and
therapeutic interventions of suspicious nodules identified through
lung cancer CT screening programs; and (vi) integration of smoking
cessation practices into future national lung cancer CT screening
programs.
Key Words: Lung cancer, CT screening, Radiology, CT screening
recommendations, IASLC workshop 2011.
(J Thorac Oncol. 2012;7: 10–19)
In November 2010, results from the National Lung Screen-ing Trial (NLST), sponsored by the National Cancer Insti-
tute (NCI) in the United States, showed that lung cancer
deaths fell by 20% and all-cause mortality fell by 7% when
smokers—defined as current or former smokers with 30 or
greater pack years of smoking—were screened annually for 3
years using low-dose spiral computed tomography (LDCT)
compared with standard chest x-ray. The study followed
more than 53,000 current and former smokers aged 55 to 74
years. It was halted because the reduction in cancer deaths
provided an answer to the study’s main question. This an-
nouncement by the Director of NCI was significant as it
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demonstrated for the first time in a randomized trial that the
early detection of lung cancer could significantly reduce lung
cancer mortality. In the wake of this landmark finding, there
has been a spirited discussion within the lung cancer com-
munity as to how and when CT screening for lung cancer
should be implemented into national programs. In parallel,
there has been considerable discussion about the potential
benefits and hazards associated with the introduction of
wide-spread ad hoc commercial screening. Shortly after the
NCI Press release on the NLST trial,1 the International
Association for the Study of Lung Cancer (IASLC) Board of
Directors requested the Chair of the IASLC Early Detection
and Prevention Committee in December 2010 convene a Task
Force to develop an IASLC position statement. The Remit of
the Task Force was to develop recommendations on (i) the
significance of low-dose CT; and (ii) the appropriate work-up
for screen-detected lung cancers. The core task force group
focused on the former question. The membership of the core
task force was based on individuals who were currently
undertaking national randomized controlled trial (RCT)
screening trials; in addition, expert clinical groups were
organized to include international representatives from other
spiral CT research groups.
The IASLC CT screening task force concluded that the
NLST spiral CT screening trial was the first randomized trial
to demonstrate a significant reduction in lung cancer mortal-
ity, but there was a range of other published data regarding
aspects of optimization of the many components of popula-
tion-based CT detection of early lung cancer. This innovation
provided a great opportunity for lung cancer clinicians and
researchers across the world to work responsibly to provide,
study, integrate, and refine this new approach within future
clinical trials and national screening programs.2
The Task Force’s Position Statement outlined a number
of the major opportunities to further improve this approach.
Based on experience with cancer screening from other organ
sites, especially breast cancer, there is a need to introduce
quality control measures to ensure the quality of the screening
management. The most critical aspect of this is that lung
cancer screening should be performed by a multidisciplinary
team experienced in evaluation and management of early
lung cancer. This involves a number of linked components of
optimal care beginning with defining the target cohort, opti-
mizing the image acquisition and interpretation, working up
the suspicious nodules, operating safely on the detected cases,
and then maintaining ongoing surveillance in an effective and
economical fashion. There are a number of trials currently
under way that could provide relevant data.3–5 One of the
largest is the Dutch-Belgian-Danish NELSON, a population-
based trial of more than 20,000 smokers, which uses stan-
dardized, high-resolution CT imaging techniques including
the use of change in nodule growth as a filter for selecting
clinically aggressive cancers to guide invasive diagnostic
work-up.6 The ongoing results of the NELSON trial will
provide additional information not only on mortality advan-
tage but also on the cost impact of a uniformly applied and
optimized approach to the clinical management of lung can-
cer screening. In light of these positive developments, each
nation will decide how to integrate lung cancer screening into
its existing healthcare structure. Given the high mortality of
lung cancer with conventional diagnostic approaches, in
some national settings, the public may be proactive in seeking
access to lung cancer screening services. Although this ap-
proach may benefit some, there are also important health risks
associated with CT-based screening. Ensuring the dissemina-
tion of responsible information to both primary care physi-
cians and patients regarding this new approach will be a
critical challenge that must be addressed in a culturally
appropriate fashion. The Position Statement stated that
to inform the process of implementation of lung cancer
screening at a national level, the IASLC will assemble and
disseminate information about the relevant evidence regard-
ing the range of specific issues with implementing and opti-
mizing lung cancer screening care:
i. Define optimal risk populations who will benefit from
screening.
ii. What is the cost-effectiveness of CT screening?
iii. Harmonization of the CT screening protocols to an
acceptable level of consistent performance, utilizing
volumetric analysis.
iv. Define the value of the individual work-up techniques,
standardization of performance, and defining appro-
priate sequence.
v. Define the optimal surgical management of patients
with screen-detected nodules.
vi. Define the optimal screening interval and the number
of screening rounds for both screen-negative and
screen-positive individuals.
vii. Hosting forums to encourage research collaboration
around improving screening outcomes while reduc-
ing the cost and complications of this management
approach.
The recommendation was to support phased, interna-
tionally coordinated “demonstration projects,” for different
geographic regions and in countries that are not currently
undertaking large RCTs. A consensus emerged that based on
positive reports, smoking cessation programs should be inte-
grated into these CT screening programs. The Task Force was
confident that the initial findings from NLST that CT screen-
ing save lives would be generalizable. Therefore, subject to
national review processes and following the concept of “in-
formed decision making,” the recommendation that CT
screening could be implemented at national levels is subject
to local considerations. This was reflected in the IASLC
Position Statement on CT Screening which was published to
coincide with the publication of the NLST article in The New
England Journal of Medicine.7 The United Kingdom Lung
Cancer CT Screening (UKLS) trial team published a Position
Statement with a similar content but with additional recom-
mendations to those who might be considering offering
screening in the United Kingdom.8
STRATEGIC PLAN FOR PROGRESS
The IASLC CT screening workshop brought together
the expertise of radiologists, pulmonologists, surgeons, pa-
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thologists, and cancer screening experts across the globe. Most
of the participants have been involved in the design and execu-
tion of CT screening trials. The combined expertise of this
multinational, multidisciplinary group positions the IASLC to
take a leading role among professional societies in developing
guidelines for CT screening implementation across the world.
A major strategic decision was made to formalize the
IASLC Expert Working Groups to serve multiple purposes:
(1) to identify and prioritize the remaining unanswered ques-
tions about optimal screening technology, assisting with the
design of demonstration projects that could address these
concerns; (2) to advise on standards for CT screening imple-
mentation in collaboration with appropriate professional or-
ganizations and accreditation bodies internationally; and (3)
to coordinate efforts with other organizations that are con-
templating the development of guidelines.
A number of questions remain outstanding and should
be prioritized for systematic assessment. Among these are
how to define an optimal, standardized definition of screen
positivity based on nodule features (diameter and volume)
that will maximize specificity. In addition, the resolution of
CT screening continues to rapidly improve, which means that
the trend to detect even smaller primary lung cancers will
continue. This is a positive trend as smaller primary tumors as
shown by the IASLC staging data are less likely to be
metastatic.9 Smaller primary lung cancers may also allow
more tailored surgical or other interventions to control the
primary tumor to further reduce the cost or complication rate
of this management. These evolving management issues are
where the IASLC multidisciplinary nature can bring value by
sustaining the research environment across its global mem-
bership to facilitate such progress.
The Core Task Force and Screening Implementation
Group recommended the importance of gathering more data
and establishing standards before introducing lung cancer
screening to assure optimal outcomes and patient safety.
However, clearly there will be variable rates of national
implementation of screening across various countries. The
Core Group reemphasized the importance of completing the
ongoing European CT RCTs. However, RCTs not yet initi-
ated might consider converting to demonstration projects or
answering specific screening management questions not yet
examined in an RCT.
The following recommendations were made by the
Core Task Force and Screening Implementation Group:
Y Encourage new screening-related research, i.e., risk
stratification, new technology, and biomarkers.
Y Quality standards must be developed, endorsed, and em-
braced before offering screening. Quality standards must
be adhered to in organized and individualized settings, with
standardized reporting of outcomes and continuous quality
improvements.
Y Smoking cessation programs should be included in all
CT lung screening programs; however, minimal stan-
dards for such programs need to be implemented.
Y IASLC should partner with relevant organizations to
define best practices at this time, disseminate best prac-
tices, encourage ongoing research, and screening pro-
grams should monitor and report findings. At this time,
there is no common consensus regarding international
CT screening quality standards (QA).
Y Within the next several months, IASLC should partner
with professional societies already developing QA stan-
dards and convene workshops to rapidly evolve consen-
sus QA guidelines for lung cancer CT screening which
then can be disseminated as soon as possible.
Y The IASLC should offer support for information ex-
change for groups seeking to initiate new screening
research studies and demonstration projects.
Y The IASLC should explore offering training workshops
focused on best practices in implementing and sustain-
ing CT lung cancer screening programs.
Y IASLC should promote the concept of multidisciplinary
diagnostic coordination, collaborate with professional
societies to identify best practices, and disseminate these
recommendations.
Y IASLC should provide support for a Strategic CT
Screening Advisory Committee (SSAC) and the on-
going deliberations of the expert workgroups focused on




Establishing the efficacy of low-dose helical CT in
reducing lung cancer mortality is a necessary but preliminary
first step toward its rational implementation for population
screening. The efficacy of CT observed in the NLST was
achieved in a controlled setting at sites with medical expertise
and resources. It involved standardized processes for image
acquisition, interpretation, report communication, and fol-
low- up data collection, had the benefit of diagnostic guide-
lines developed by radiologists trial-wide, and relied on
rigorous end point verification by an independent committee
of physicians.7,10
With large-scale implementation, uniform standards
throughout the screening process will be imperative. Stan-
dardization ensures quality control, promotes the more accu-
rate assessment of the evolution of nodules over time at
individual institutions, improves the comparison of results
across different institutions and within different trials, and
ensures the maximum benefits relative to risks among scree-
nees. These types of quality control measures are being
recommended for clinical trials but also are critical in routine
healthcare delivery sites to ensure the quality of those pro-
cesses as well.11 The IASLC Radiology Working Group
identified the need for standards in multiple areas:
1. Equipment standards, calibration, and regular monitoring;
2. Uniform acquisition parameters that optimize image
quality at minimum radiation doses;
3. Standardized approaches to image and nodule analysis,
with attention to software requirements for quantitative
analysis;
4. The use of controlled vocabularies to standardize fea-
ture analysis, screening interpretations, and communi-
cation of results;
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5. Standardization of follow-up algorithms;
6. The collection of necessary screening outcomes to mon-
itor and guide screening practices.
The standardization of screening practices will neces-
sarily be iterative and must account for differences in tech-
nological resources internationally. A strategic approach to
address this is a tiered guideline that defines two levels of
standardization: (1) optimal processes, which serve as the
benchmark for large-scale screening, and (2) satisfactory
processes to accommodate differences in availability of tech-
nical resources. A major point of discussion is the approach
to nodule assessment. The NELSON6 and other screening
trials12,13 have shown excellent results with the use of nodule
volumetry and have validated the higher reproducibility of
volumetric measurement and its greater sensitivity to size
change relative to manual two-dimensional (diameter) mea-
sures. Although not presently feasible in all screening envi-
ronments, there was wide acceptance among members that
nodule volumetry should be the optimal benchmark.
There has been no large-scale project that specifically
addresses the overall impact on long-term outcomes of nod-
ule analysis using two-dimensional diameters versus nodule
volumetry. Such a demonstration would be important in
guiding the directions that should be taken in standardizing
nodule assessment over time.
Finally, the large-scale implementation of screening will
tax most medical systems. Nodule volumetry software and
training of nonphysician image analysts to perform quantitative
image analyses may be essential to the feasibility of high-risk
population screening. The IASLC Radiology Working Group
will develop imaging standardization consistent with best prac-
tices for both manual two-dimensional and semi-automated
three-dimensional quantitative assessment as well as other dis-
criminating features of nodule characterization.
DEFINING SCREEN POSITIVITY
A major challenge of LDCT screening is the high
false-positive rate, which exposes screenees to unnecessary,
potentially deleterious diagnostic evaluations and psycholog-
ical discomfort. The definition of screen positivity represents
a compromise between high sensitivity (fewer missed can-
cers) and high specificity (fewer false-positive screens). In
the NLST, screen positivity was defined by greatest nodule
diameter of 4 mm or larger.1 Overall, 24% of all CT screens
were positive using this definition. In contrast, the NELSON
trial based screening interpretation on nodule volumetry and
used a tiered approach. They classified nodules less than 50
mm3 (4.6-mm diameter) as negative, nodules greater than
500 mm3 (9.8-mm diameter) positive, and nodules 50 to
500 mm3 indeterminate. Indeterminate nodules underwent an
early (3-month) follow-up LDCT to assess for growth; nodule
volume doubling times were then used to distinguish between
positive screens requiring additional diagnostic procedures
and negative screens.6 Using this two-step approach, 2.6% of
NELSON baseline screens were positive, and a higher pro-
portion of positive screens were due to lung cancer.
The use of nodule volumetry mandates that image
acquisition provides isotropic datasets of high spatial resolu-
tion while minimizing physiologic motion. In the NELSON,
image datasets were acquired using 16-detector row scanners
at 1 mm thickness with 0.7 mm overlapping reconstruction.
The volumetric software (LungCare, version Somaris/5
VA70C-W, Siemens Medical Solutions, Erlangen, Germany)
is one of several commercially available and can be used with
CT data in DICOM format from any scanner platform.11 In a
sample of nodules of varying size, these investigators have
observed high interobserver correlation (r  0.99) with
discrepant results seen in 10.9% of cases, typically amounting
to less than 10% discrepancy. Discrepancies are most com-
mon with very small nodules (30 mm3) because of volume
averaging effects in which the outer voxels of the nodule fall
outside the threshold for analysis and in larger nodules with
irregular shape, irregular margins, or spiculation.14,15
Using volumetric analysis to define positivity as an
increase in nodule volume of at least 25% between two scans
in nodules between 50 and 500 mm3, the NELSON trial
reported a screen sensitivity of 94.6% (95% confidence in-
terval [CI]: 86.5–98.0) and a negative predictive value of
99.9%. The performance characteristics of screening CT in
the NLST have not yet been reported.
Ground-glass nodules (GGN) pose unique problems
for assessing evolution, as volume growth may be subtle.
The notion of nodule “mass” has been proposed, in which
nodule evolution (growth) is based on changes in the
product of nodule volume and average density. The mea-
sure of mass is more sensitive to the development of solid
components in GGN, which are known to be highly asso-
ciated with malignancy.16
The mortality results of the NELSON trial are pending,
but the unique methodological features of this randomized
trial have yielded important insights that complement the
information gained from NLST. Volumetric analysis prom-
ises greater reproducibility and accuracy in nodule character-
ization. It will fall to the individual medical communities to
determine whether the performance improvement using nod-
ule volumetry outweighs the inevitable alterations in radiol-
ogist workflow and incremental costs of dedicated analytical
workstations, software, and staff. Alternatively, there may be
technological innovation related to host web services that
could emerge as a reference resource in providing support to
volume analysis approaches, and this is an area where further
research should be encouraged.
MULTIDISCIPLINARY TEAM WORK-UP OF
POSITIVE CT-SCREENED NODULES
The pulmonary group supported the concept that co-
horts with high risk of developing lung cancer may be offered
screening as already discussed. This approach has been used
in the UKLS trial17 where the Liverpool lung project risk
prediction model is used to select high-risk individuals.18
When a suspicious nodule is found based on a priori defined
criteria, that case should undergo subsequently follow-up to
assess for growth. Cases that demonstrate significant nodule
growth should be referred to a multidisciplinary group with
expertise in lung cancer for further work-up. It was noted that
only those who are at a high risk of developing lung cancer
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should be offered screening and so when a nodule is found,
criteria for a positive result should be predicated on this. The
pulmonology group agreed with current standards that nod-
ules smaller than 4 to 5 mm in diameter (or equivalent
volume) should be followed up on their first annual repeat
screening. For larger nodules, where additional work-up is
recommended in a shorter time frame, there will also be some
size cutoff where these should be referred directly to the
multidisciplinary group. The suggestion was that 8 mm con-
stituted a reasonable threshold. Size criteria for both a posi-
tive result and referral to the multidisciplinary group will be
further refined by analysis of data from various research
groups that have already amassed large databases of nodules
with their attendant outcomes. The aim of this analysis will
be to optimize the specificity/sensitivity characteristics of the
screening process. This will entail establishing the size (and
other nodule characteristics) that will minimize both the
number of cases requiring additional work-up and the number
of cases of cancer that are classified as a negative screen at
baseline, while minimizing the occurrence of interval-de-
tected cancers. The ground-glass (nonsolid) nodule was rec-
ognized as being particularly promising in terms of redefining
the size cutoff for a positive result as it is recognized that they
are particularly slow growing and when diagnosed as cancer,
highly amenable to treatment.
Among those abnormalities not meeting the criteria of
positive result, the recommendation for annual repeat screen-
ing is advised although additional considerations may alter
this as new data emerges. In this situation, the results do not
need to go to the multidisciplinary team and can be referred
to either a nurse or primary or secondary care physician to
continue screening at appropriate time intervals.
The work-up algorithm for nodules above the thresh-
old size for being considered positive will also have
management determined largely by size criteria. Growth
assessment will remain a key determinant of the work-up,
and definitions as to what constitutes true growth are being
formulated. The relationship of initial size of nodule to the
interval between baseline and repeat scan is also uncertain
and will be informed by analysis of existing data. Once
interval primary tumor growth is established, further eval-
uation with either positron emission tomography CT or
tissue sampling may be useful. Tissue sampling will de-
pend on a number of factors including the patient and
nodule characteristics and local expertise in performing
these procedures. For tissue sampling, bronchoscopy with
navigation techniques is now emerging as a useful ap-
proach (for larger nodules) along with transthoracic core
needle biopsy and thoracoscopy. To determine the relative
utility of bronchoscopic compared with percutaneous CT-
directed biopsy approaches is an important research ques-
tion, particularly to determine the safest, most effective,
and most economical approach to diagnostic work-up.
There may also be some threshold size (10 –15 mm) where
a decision to go directly to tissue sampling may be rea-
sonable. Defining the actual size threshold constitutes
another important area for research. The molecular char-
acterization of tumors detected by CT screening compared
with clinically detected tumors is another area of interest
for future research.
As with any screening approach, participants enroll-
ing in a lung cancer screening trial should have a baseline
level of fitness that will allow them to benefit from early
detection and treatment of lung cancer. This should include
generally healthy, asymptomatic individuals with a will-
ingness to undergo treatment if necessary and an approx-
imate 10-year life expectancy. Various risk assessment
models and algorithms for patient fitness may have an
important role in deciding eligibility for enrollment into a
screening program.
SURGICAL ASPECTS OF THE
IMPLEMENTATION OF CT SCREENING
A major risk factor in CT screening is the large number
of indeterminate pulmonary nodules that will be detected and
may require diagnostic interventions. In the NLST screening
trial, at prevalence screen, the false positivity rate was found
to be more than 95%.7 Inappropriate surgical interventions
may put the screened population at risk, to a much higher
degree than in other cancer screening programs, because the
surgery itself caries a higher risk. However, well-performed
surgery may often offer the best chance of early diagnosis and
cure for this otherwise lethal disease. It is essential that
surgeons undertaking treatment and diagnostic procedures in
a screening setting are sufficiently qualified and prepared for
this task.
The Surgical Expert Group proposes specific require-
ments for future lung cancer screening trials. Surgeons should
be involved in the set up and design of any future screening
or demonstration programs as well as in the diagnostic
process as in the multidisciplinary meetings. This group also
considered it was important that the surgeon be experienced
in thoracic surgery and in evaluating pulmonary CT scans. It
is strongly recommended that surgery be performed in centers
with access to a full minimally invasive surgical program,
including the ability to perform video-assisted thoracoscopic
surgery (VATS) anatomical resection when appropriate. Ro-
botic surgery with lobectomy is at present under development
and may be an option in some centers. This group recom-
mended that a formal protocol for the diagnostic and surgical
management be prepared.
Surgical participation in work up of detected nodules
was based on the workshop recommendations from the Ex-
pert Radiology Group. In screenees with indeterminate nod-
ules, the purpose of the surgical diagnostic intervention is to
obtain pathological proof of the character of the nodule. The
decision to go ahead with surgery depends on many factors
including number of nodules, patient condition, and comor-
bidity. Several radiological diagnostic guidelines exist in-
cluding those proposed by the Fleischner Society in 2005,19
the American College of Chest Physicians,20 from Japan,21
and from Italy.22 This is a crucial area for further research, as
the clinical management of suspicious nodules will greatly
influence the efficiency and cost of the overall screening
process. Although demonstration of primary tumor growth is
emerging as a promising approach to minimize overdiagno-
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sis, the definitions vary as to what constitutes significant
growth and how to manage the consequences of those mea-
surements. Volumetric evaluation used by NELSON seems to
be more precise and results in low number of false-positive
test results (1.8–3%).6 Nodule volume doubling time less
than 400 days has been proposed as an indication of malig-
nancy and for surgical exploration.6 The UKLS have recently
published the nodule management protocol which will be
used in the United Kingdom, which has used many of the
NELSON principles.17 There is an urgent need for harmoni-
zation of radiological guidelines.
The Surgical Group was of the opinion that the use of
CT-guided biopsy for suspicious nodules should be encour-
aged and will in many cases facilitate the surgical decision
process.23,24 The involvement and expertise of interventional
radiologists or pulmonologists specialized in minimally inva-
sive biopsy using percutaneous, navigational bronchoscopy
and endobronchial ultrasound techniques are important. Fur-
ther research to define a potential role for positron emission
tomography in characterization of small pulmonary nodules
is a near-term opportunity.
The surgical techniques used for excision of indetermi-
nate nodules will most often be a minimally invasive wedge
resection depending on the location and the size of the lesion.
With small primary lung cancers, thoracotomy will be re-
quired less than in the past. The natural history of small
nodules below 10 mm and especially ground-glass opacity
lesions is not yet fully defined. In addition, it may be difficult
to locate such small primary tumors for excision. Therefore,
the experience of the surgeon in primary localization is
important and subject to further research, and longer obser-
vation time may be justified until growth is unequivocally
established. Methods for the location and marking of small
nodules are still cumbersome and not widely used. Improved
technology in this area could have a great impact on patient
management and safety.25 When a diagnosis of lung cancer is
known or suspected preoperatively, the preoperative investi-
gations follow standard guidelines according to tumor, node,
metastasis staging and condition of the patient.26
Surgical treatment options were also considered by this
Expert Group. In general, anatomical resection by lobectomy
with systematic nodal dissection is the recommended treat-
ment. Reports from Society of Thoracic Surgeons and other
groups have been published evaluating video-assisted surgi-
cal approaches compared with open thoracotomy to manag-
ing small primary lung cancers with favorable results.27–29
For small peripheral lung cancers below 2 cm, more limited
surgical approaches are being studied in two ongoing ran-
domized clinical trials. In the United States, the CALBG trial
(CALBGI140503 protocol) compares wedge and anatomical
segmental resection with lobectomy. The Japanese Clinical
Oncology Group trial compares segmental resection with
lobectomy.27 However, the result of these trials will only be
available in 5 to 10 years time. However, until then, it is
recommended that anatomical segmentectomy be reserved
for the CT screening-detected pure ground-glass opacity
lesions or part-solid lesions below 2 cm located in the
peripheral third of the lung, after frozen section of N1 and N2
lymph nodes have confirmed the T1aN0M0 status. In addi-
tion, frozen section or cytological evaluation of resection
margins is recommended.
Patients with reduced pulmonary reserve or multiple
lesions requiring excision are also suitable for segmental
resections, even for solid lesions. Minimally invasive surgical
techniques by qualified surgeons are strongly recommended.
HANDLING OF PATHOLOGY SPECIMENS
FROM CT-SCREENED PATIENTS
Increased use of CT screening for lung cancer will
greatly impact the number and type of pathology specimens.
The following comments are directed at lung cancer speci-
mens and do not address issues related to the “false positive”
situation where a benign diagnosis is obtained.
As CT-guided preoperative biopsies will play an im-
portant role in evaluation of CT-detected lung nodules, offi-
cial guidelines for diagnostic terminology and criteria for
lung cancer diagnosis based on small biopsies and cytology
were recently provided by the 2011 IASLC/American Tho-
racic Society/European Respiratory Society lung adenocarci-
noma classification.30 Although 70% of lung cancer patients
overall present in advanced stages,30 in CT-screened lung
cancers, approximately 20% are advanced stage (stages IIIB
and IV) and 80% are resectable (stages I–IIIA).7 In experi-
enced hands, a fine needle biopsy can be used to evaluate a
screen-detected nodule with sensitivities up to 90%. The
availability of an on-site cytologist or pathologist can be
helpful but it is not essential.
For resected lung cancers, pathology specimens should
be processed according to established protocols.31 Tumors
should be classified according to established pathologic cri-
teria such as the 2004 World Health Organization classifica-
tion32 and 2011 IASLC/American Thoracic Society/European
Respiratory Society adenocarcinoma classification.33 In the
new lung adenocarcinoma classification, there are several
major conceptual changes that have important implications
for pathologic processing of early lung adenocarcinomas that
are likely to be detected by CT screening. First, the term
bronchioloalveolar carcinoma is no longer used. For the early
adenocarcinomas that were previously classified as bronchi-
oloalveolar carcinoma, there are three newly defined entities
that are likely to correspond to small solitary tumors that by
CT appear as pure GGN or part-solid nodules with a predom-
inant ground-glass component.30 These include adenocarci-
noma in situ (AIS), minimally invasive adenocarcinoma
(MIA), and lepidic predominant adenocarcinoma. AIS and
MIA are small solitary 3 cm tumors that should have a
100% or near 100% 5-year survival, respectively, if com-
pletely resected. AIS have pure lepidic growth without inva-
sion, and MIA is a lepidic predominant tumor with 0.5 cm
invasive component.33,34 Lepidic predominant adenocarcino-
mas have a predominant lepidic growth pattern with more
than 0.5 cm of invasive component, and these may be
larger than 3.0 cm. Five-year disease-free survival for
resected tumors is approximately 90%.34 It is also hypothe-
sized that the size T factor may be better assessed by mea-
suring invasive size rather than total size including the lepidic
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component. This may be applicable to CT assessment of
tumor size for clinical staging with GGN or part-solid nod-
ules. Potentially, AIS may be classified as Tis (adenocarci-
noma) and MIA may be Tmi. However, this is a proposal that
needs to be validated in multiple radiologic and pathologic
datasets, before it can be officially adopted by the Union
Internationale Contre le Cancer/American Joint Cancer Com-
mittee tumor, node, metastasis classification.
THE ROLE OF INDUSTRY
A major requirement for large-scale screening imple-
mentation is the availability of commercially available
screening management systems that expedite and standardize
reporting, reminders, the documentation of screening results,
and recording results of downstream diagnostic tests in a
database that can be readily interrogated. The Radiology
Committee identified the development of screening manage-
ments systems as a major need and opportunity for industry
to collaborate with qualified institutions to understand work-
flow, standards, and data elements that form the blueprint for
such management systems.
Similarly, a critical need for industry is the availability
of image datasets acquired at high (isotropic) resolution
across all commercial CT platforms that can be used to
validate analytical software for nodule volumetry and feature
extraction. Datasets that provide a standard of truth against
which commercial software can be tested as well as “coffee
break” imaging exams to measure repeatability should be
goals of multinational collaborations moving forward. An
example of this is the recent effort by Oxnard et al. in which
they performed comparative radiological analysis in a series
of “coffee break” cases and then made those DICOM files
available for further research through the NCI’s web-
site.16,28,29,35 The routine donation of image files from screen-
ing research studies is a practice that the IASLC has to
strongly encourage to allow more rapid progress in this new
but promising area.
THE ROLE OF STANDARDIZATION IN
SCREENING IMPLEMENTATION
The widespread implementation of LDCT screening for
lung cancer can borrow lessons from the implementation of
breast cancer screening36,37 but will also impose significant
new challenges. For the imaging community, LDCT screen-
ing will require a high standard: sophisticated multidetector
CT scanners and analytical software, professional physicists,
and staff who can certify equipment and perform studies to a
consistent standard at acceptable radiation exposures, ongo-
ing imaging quality assurance,38 qualified radiologists who
use controlled terminologies and standardized interpretation
guidelines, reliable communication requirements with pri-
mary care physicians, medical environments that can absorb
patients who require ongoing management, and the respon-
sibility of tracking screened individuals and documenting
outcomes.
CT screening benefits outweigh risks in the setting of
high-risk cohorts, but its cost-effectiveness must be quanti-
fied. Cost-effectiveness analyses of CT screening have been
modeled by different groups and have reached varying con-
clusions.39–42 A formal cost-effectiveness analysis from a
societal perspective is also in progress using NLST data that
will compare CT screening with chest radiography and no
screening across time horizons both within trial and lifetime.
This analysis will be fundamental to future guidelines devel-
opment. Depending on the results of such analyses, primary
providers may be challenged to agree that LDCT screening is
a health priority to tolerate disruption of normal workflow,
and to divert time, resources, and patient education from
other evidence-based preventive measures. For the public, the
challenges will be the equitable implementation of screening
across all socioeconomic strata at risk. This is particularly
important for lung cancer, in which a disproportionate burden
of the disease affects individuals in disadvantaged commu-
nities, often because of lack of awareness of lung cancer risk,
financial limitations, fears of radiation and other screening-
associated interventions, and the unique cultural concerns of
trust, fatalism, and stigmatization associated with medical
screening and practice.43–45
The efficacy of CT screening can be greatly enhanced
if positioned in multidisciplinary programs that offer com-
prehensive coordination of care between primary and subspe-
cialty providers and in which aggressive smoking cessation
programs are readily available. CT screening provides a
potentially teachable moment for smoking cessation but
should be further advantaged to sustain smoking abstinence
long term.46–48 If achievable, CT screening, smoking cessa-
tion, and ultimately chemoprevention opportunities in high-
risk smokers could dislodge lung cancer from its current
position as the primary cancer killer to a curable disease.
It was concluded that only through rigorous quality
control and follow-up would we attain the best results from
CT screening programs. The Expert Surgical Group made a
very clear recommendation that all surgeons involved in
screening programs should be qualified in chest surgery, in
particular that the surgeons performing VATS surgery should
have performed at least 15 VATS lobectomies independently.
The IASLC could work with other professional societies to
evolve a training program to keep clinicians abreast of the
fast-moving developments for lung cancer screening manage-
ment and to ensure all clinicians are trained on new clinical
management techniques. The outcome of all surgery should
be monitored with regard to mortality, morbidity, and nodal
evaluation, in addition to the conversion rate to thoracotomy
during VATS surgery. Surgeons should minimize the number
of resections for benign disease (based on the data that is
available from trials to date, this should be below 15%). To
achieve this objective, it is recommended that the formal
protocol and guidelines for the surgical management are
adhered to within a multidisciplinary environment and that
outcomes on these parameters are shared with the public so
that high quality of care is maintained.
At national levels, there should be systematic registra-
tion and documentation of all screening-related lung cancer
cases in a formal database, as well as all screening-related
surgery and other participant-related interventions.
Field et al. Journal of Thoracic Oncology • Volume 7, Number 1, January 2012
Copyright © 2011 by the International Association for the Study of Lung Cancer16
The end goals of lung cancer screening are to reduce
the morbidity and mortality of lung cancer. We are at the
cusp of implementation; improvements in screening will
necessarily require a systematic, multifaceted approach
across multiple medical disciplines. The complementary
use of molecular biomarkers to identify those at risk who
should undergo screening or more aggressive diagnostic
strategies for positive screens is considered achievable in
the near future.
Optimal practices for the community, the primary set-
ting, and screening programs can only be understood and
measured through funding for demonstration projects, which
must be a critical priority in order for lung cancer screening
to be rapidly and successfully implemented.
FUTURE PRIORITIES
The IASLC Board of Directors has agreed to set up the
SSAC. The SSAC is currently engaging professional societ-
ies and organizations who are stakeholders in lung cancer CT
screening implementation across the globe to focus on deliv-
ering guidelines, and recommendations in six specific areas:
1. Identification of high-risk individuals for lung cancer
CT screening programs.
2. Develop radiological guidelines for use in developing
national screening programs.
3. Develop guidelines for the clinical work-up of “inde-
terminate nodules” resulting from CT screening pro-
grammers.
4. Guidelines for pathology reporting of nodules from
lung cancer CT screening programs.
5. Recommendations for surgical and therapeutic inter-
ventions of suspicious nodules identified through lung
cancer CT screening programs.
6. Integration of smoking cessation practices into future
national lung cancer CT screening programs.
IASLC recognizes the importance of engaging the
major international stakeholders in lung cancer CT screening
to develop these guidelines and recommendations and is
currently taking this initiative forward.
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